Antengene presents strong clinical data update at JPM, focusing on next-gen ADCs and TCEs.SEHK:. Jan 15, 2026.
On January 15, 2026, Antengene Corporation Limited (SEHK: 6996.HK), a top global biotech firm, based in Shanghai and Hong Kong, is committed to innovating and commercializing advanced medicines. Antengene focuses on developing and marketing cutting-edge drugs, striving to lead the way in the industry.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments